Abrax

Sirolimus – Eluting Biodegradable Polymer Stent System
“DES Re-discovered”

Abrax ^TM Sirolimus-Eluting Stent System is designed to perform successfully even in the
most demanding cases. The combination of Sirolimus’ antiproliferative action coupled
with Rontis’ biodegradable polymer and proven balloon catheter ensures effective
treatment of clinically difficult lesions with confidence. This essentially means that
patients who receive Abrax ^TMare a lot less likely to need another repeat procedure in the short term.

Biodegradable polymer

• PLGA
• Uniform and site-specific drug delivery
• Thin layer 5 μm
• Complete degradation following the drug release into 6 weeks
• Eliminating inflammation and stent thrombosis

Stent platform

• Carbon ionized surface for higher biocompatibility and reduced restenosis rateCarbon ionized surface for higher biocompatibility and reduced restenosis rate
• DATS Technology (Dual Anti-Thrombogenic Stent Technology)
• MSC Design (Multivariate Stent Cell )
  This design offers generous access for ballooning and stenting hemodynamically prominent coronary side-branches in order to optimize intramyocardial blood flow to subendocardial and intramural microvasculature.
• Intra-cellular “sinusoidal links”
• Open cell design ensures balance of radial strength and flexibility
• Enhanced radiopacity
• Optimal scaffolding as well as stent-to-wall apposition with superior acute gain

Balloon catheter platform

• Lower inflation pressuresLower inflation pressures
• Homogenizes stent expansion
• Hydrophilicity lowers friction optimizing deliverability

Sirolimus

• Suppresses neointimal growth without suppressing endothelialization
• Reduces in-stent restenosis
• Drug load 2.0μg/mm2

Klinik fûr Herz und Kreislauferkrankungen, Munich (Germany)

Abrax ^TM Sirolimus – Eluting Biodegradable Polymer Coronary Stent System

Stent Specifications

Polymer/Drug Specifications